Board Change • May 20
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. R&D Director and Supervisor Ronghao Li is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 공시 • Apr 23
Bide Pharmatech Co., Ltd., Annual General Meeting, May 13, 2026 Bide Pharmatech Co., Ltd., Annual General Meeting, May 13, 2026, at 09:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China 공시 • Mar 30
Bide Pharmatech Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 Bide Pharmatech Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 공시 • Dec 26
Bide Pharmatech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026 Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026 공시 • Sep 30
Bide Pharmatech Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Bide Pharmatech Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 공시 • Jun 30
Bide Pharmatech Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025 Bide Pharmatech Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025 공시 • Apr 24
Bide Pharmatech Co., Ltd., Annual General Meeting, May 14, 2025 Bide Pharmatech Co., Ltd., Annual General Meeting, May 14, 2025, at 14:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China 공시 • Mar 28
Bide Pharmatech Co., Ltd. to Report Q1, 2025 Results on Apr 24, 2025 Bide Pharmatech Co., Ltd. announced that they will report Q1, 2025 results on Apr 24, 2025 공시 • Feb 10
Bide Pharmatech Co., Ltd. (SHSE:688073) announces an Equity Buyback for CNY 100 million worth of its shares. Bide Pharmatech Co., Ltd. (SHSE:688073) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be purchased at a price not exceeding CNY 72.30 per share. The purpose of the program is to improve the company's long-term incentive mechanism, fully mobilize the enthusiasm of the employees, and jointly promote the company's long-term development. The repurchased shares will be used for employee stock ownership plans or equity incentive plans, otherwise will be cancelled if the company fails to transfer them within the time limit stipulated by relevant laws and regulations. The program will be funded from company's own funds and special loans. The program will be valid for 6 months. 공시 • Jan 22
Bide Pharmatech Co., Ltd. (SHSE:688073) agreed to acquire an unknown minority stake in Zhuhai Weibo Investment Co., Ltd. from Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership) managed by Vivo Capital, LLC and Vivo Equity Investment Management (Shanghai) Co. Ltd. Bide Pharmatech Co., Ltd. (SHSE:688073) agreed to acquire an unknown minority stake in Zhuhai Weibo Investment Co., Ltd. from Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership) managed by Vivo Capital, LLC and Vivo Equity Investment Management (Shanghai) Co. Ltd. on January 21, 2025. The consideration consists of common equity of Bide Pharmatech Co., Ltd. to be issued for common equity of Zhuhai Weibo Investment Co., Ltd. As part of consideration, an undisclosed value is paid towards common equity of Zhuhai Weibo Investment Co., Ltd. 공시 • Dec 27
Bide Pharmatech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 24, 2025 Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 24, 2025 Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥42.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.33 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.36 (up from CN¥0.33 in 3Q 2023). Revenue: CN¥279.2m (down 1.1% from 3Q 2023). Net income: CN¥32.0m (up 8.2% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥33.82, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥44.40 per share. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to CN¥37.43, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.54 per share. 공시 • Sep 30
Bide Pharmatech Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Bide Pharmatech Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.51 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.29 (down from CN¥0.51 in 2Q 2023). Revenue: CN¥269.5m (flat on 2Q 2023). Net income: CN¥25.8m (down 45% from 2Q 2023). Profit margin: 9.6% (down from 17% in 2Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. 공시 • Jun 29
Bide Pharmatech Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024 Bide Pharmatech Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024 공시 • May 15
Bide Pharmatech Co., Ltd., Annual General Meeting, Jun 03, 2024 Bide Pharmatech Co., Ltd., Annual General Meeting, Jun 03, 2024, at 14:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.41 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.29 (down from CN¥0.41 in 1Q 2023). Revenue: CN¥262.7m (up 4.0% from 1Q 2023). Net income: CN¥26.1m (down 29% from 1Q 2023). Profit margin: 9.9% (down from 15% in 1Q 2023). Revenue is forecast to grow 33% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. 공시 • Mar 29
Bide Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Bide Pharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥36.16, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Reported Earnings • Feb 03
Full year 2023 earnings released: EPS: CN¥1.24 (vs CN¥1.98 in FY 2022) Full year 2023 results: EPS: CN¥1.24 (down from CN¥1.98 in FY 2022). Revenue: CN¥1.09b (up 31% from FY 2022). Net income: CN¥113.0m (down 23% from FY 2022). Profit margin: 10% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥39.88, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 16x in the Pharmaceuticals industry in China. 공시 • Dec 30
Bide Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024 Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024 Board Change • Nov 17
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Meng Zhang was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.